Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) is scheduled to post its quarterly earnings results on Monday, November 6th. Analysts expect Galmed Pharmaceuticals to post earnings of ($0.23) per share for the quarter.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. Galmed Pharmaceuticals had a negative return on equity of 141.13% and a negative net margin of 1,443.98%. The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.29 million. On average, analysts expect Galmed Pharmaceuticals to post $-0.96 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Galmed Pharmaceuticals Ltd. (GLMD) opened at 8.27 on Monday. Galmed Pharmaceuticals Ltd. has a 12-month low of $2.78 and a 12-month high of $9.59. The stock’s 50 day moving average price is $8.49 and its 200-day moving average price is $6.82. The firm’s market cap is $101.05 million.

GLMD has been the topic of a number of recent analyst reports. Maxim Group reiterated a “buy” rating and issued a $14.00 price objective (up previously from $9.00) on shares of Galmed Pharmaceuticals in a research report on Monday, July 31st. Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research report on Wednesday, August 2nd. HC Wainwright raised their price target on Galmed Pharmaceuticals from $12.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, Seaport Global Securities restated a “buy” rating and set a $19.00 price target on shares of Galmed Pharmaceuticals in a research report on Friday, October 6th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Galmed Pharmaceuticals has an average rating of “Buy” and an average price target of $14.75.

TRADEMARK VIOLATION WARNING: “Galmed Pharmaceuticals Ltd. (GLMD) to Release Earnings on Monday” was posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Earnings History for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with's FREE daily email newsletter.